SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bramwell B. Diffuse scleroderma: its frequency, its occurrence in stone-masons; its treatment by fibrolysin-elevations of temperature due to fibrolysin injections. Edinb Med J 1914; 12: 387401.
  • 2
    Kubota J. Occupational diseases in synthetic resin and fibre industries. J Sci Labour 1957; 33: 122.
  • 3
    Toxic Epidemic Syndrome Study Group. Toxic epidemic syndrome, Spain 1981. Lancet 1982; 2: 697702.
  • 4
    Hertzman PA, Blevins WL, Mayer J, Greenfield B, Ting M, Gleich GJ. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 1990; 322: 86973.
  • 5
    Silver RM, Medsger JrTA, Bolster MB. Systemic sclerosis and scleroderma variants: clinical aspects. In: KoopmanWJ, MorelandLW, editors. Arthritis and allied conditions. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 163380.
  • 6
    Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, Leboit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 10001.
  • 7
    Cowper SE, Su LD, Bhawan J, Robin HS, Leboit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 38393.
  • 8
    Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006; 18: 6147.
  • 9
    Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear [letter]. Am J Dermatopathol 2003; 25: 358.
  • 10
    Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005; 46: 7635.
  • 11
    Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [published erratum appears in Nephrol Dial Transplant 2006;21:1745]. Nephrol Dial Transplant 2006; 21: 11048.
  • 12
    Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 235962.
  • 13
    Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2: 2647.
  • 14
    MedWatch. URL: www.fda.gov/medwatch.
  • 15
    Food and Drug Administration, Department of Health and Human Services (US). Public health advisory. Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. URL: www.fda.gov/cder/drug/advisory/gadolinium_agents.htm.
  • 16
    Food and Drug Administration, Department of Health and Human Services (US). Health care professional sheet. URL: www.fda.gov/cder/drug/infopage/gcca/default.htm.
  • 17
    Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis predict early mortality and are associated with gadolinium exposure. Arthritis Rheum 2007; 56: 343341.
  • 18
    Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5: 491502.
  • 19
    Spencer AJ, Wilson SA, Batchelor J, Reid A, Rees J, Harpur E. Gadolinium chloride toxicity in the rat. Toxicol Pathol 1997; 25: 24555.
  • 20
    High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 216.
  • 21
    Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56: 2730.
  • 22
    Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 1992; 10: 6418.
  • 23
    Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan) [review]. Invest Radiol 2007; 42: 13945.
  • 24
    Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature [review]. Semin Arthritis Rheum 2006; 35: 23849.
  • 25
    Quan T, Cowper S, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006; 8: 14550.
  • 26
    Ortonne N, Lipsker D, Chantrel F, Boehm N, Grosshans E, Cribier B. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermat 2004; 150: 10502.
  • 27
    Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114: 43846.
  • 28
    Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006; 45: 42938.
  • 29
    Sakai N, Wada T, Yokoyama H, Lipp M, Ueha S, Matsushima K, et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci U S A 2006; 103: 14098103.